Overview
GYRE market data
Price History
GYRE price chart
Valuation & Profitability
- P/E (TTM)
- 133.73 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.05 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.37 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5.44 – $9.42 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $672.3 · P/B 6.05 · P/S 5.74.
Company news
8-K filing — GYRE THERAPEUTICS, INC. (GYRE)SEC EDGAR · Jul 16, 2026, 8:35 PM
8-K/A filing — GYRE THERAPEUTICS, INC. (GYRE)SEC EDGAR · Jul 15, 2026, 9:09 PM
Gyre Therapeutics New Drug Application For Chronic Hepatitis B Treatment Receives China's Center For Drug Evaluation AcceptanceBenzinga · May 12, 2026, 8:20 PM
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical CompanyBenzinga · May 4, 2026, 1:05 PM